<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03278548</url>
  </required_header>
  <id_info>
    <org_study_id>HC-G-H-1504</org_study_id>
    <nct_id>NCT03278548</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal Surgery</brief_title>
  <acronym>PHOENICS</acronym>
  <official_title>Prospective, Randomized, Controlled, Double-blind, Multi-centre, Multinational Study on the Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Society of Anaesthesiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the safety of a 6% HES (Hydroxyethyl Starch) solution
      (Volulyte 6%) versus an electrolyte solution (Ionolyte) in patients undergoing elective
      abdominal surgery.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 28, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in mean estimated glomerular filtration rate (eGFR) (calculated from highest cystatin-C levels measured during post-operative days 1-3 (POD 1-3)) between the two treatment groups</measure>
    <time_frame>post-operative days 1-3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculated red blood cell (RBC) loss</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated intra-operative blood loss</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>until post-operative day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin C</measure>
    <time_frame>until post-operative day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major post-operative complications</measure>
    <time_frame>until post-operative day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hypovolaemia Due to Acute Blood Loss</condition>
  <arm_group>
    <arm_group_label>Volulyte 6%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volulyte 6% solution for infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ionolyte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ionolyte solution for infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volulyte 6%</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Volulyte 6%</arm_group_label>
    <other_name>Hydroxyethylstarch 130</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ionolyte</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Ionolyte</arm_group_label>
    <other_name>Electrolyte solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion: • Male or female adult patients &gt; 40 and ≤ 85 years of age. Women of child
        bearing potential must test negative on standard pregnancy test (urine or serum)

          -  Patients undergoing elective abdominal surgery with an expected blood loss of ≥ 500 ml

          -  ASA Physical Status II - III

          -  Signed written informed consent form

        Exclusion: • Hypersensitivity to the active substances or to any of the other excipients of
        the investigational medicinal products

          -  Body weight ≥ 140 kg

          -  Sepsis

          -  Burns

          -  Renal impairment (AKIN stage ≥ 1) or acute and/or chronic renal replacement therapy

          -  Intracranial or cerebral haemorrhage

          -  Critically ill patients (typically admitted to the intensive care unit)

          -  Hyperhydration

          -  Pulmonary oedema

          -  Dehydration

          -  Hyperkalaemia

          -  Severe hypernatraemia

          -  Severe hyperchloraemia

          -  Severely impaired hepatic function

          -  Congestive heart failure

          -  Severe coagulopathy

          -  Organ transplant patients

          -  Metabolic alkalosis

          -  Simultaneous participation in another interventional clinical trial (drugs or medical
             devices studies)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>41 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang F. Buhre, Prof. Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology and Pain management, Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg AÖR</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2017</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HES</keyword>
  <keyword>Hydroxyethylstarch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

